Clinical trials: Cardiac Ischemia
Ischemic Heart Failure
LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
The WEARIT-III registry enrolls subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator.
- Trial name
- WEARIT-III (NCT02700880)
- Testing
- LifeVest
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Zoll Medical Corporation
Coronary Artery Disease
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
- Trial name
- NCT00540670
- Testing
- E5555 50 mg, E5555 100 mg, E5555 200 mg
- Where
- 25 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Coronary Artery Disease (CAD)
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
The aim of this study is to demonstrate that the combination therapy of aspirin and clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet…
- Trial name
- NCT01830491
- Testing
- Clopidogrel, aspirin 100mg
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Coronary Syndrome
Canadian Ticagrelor Survey
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns…
- Trial name
- NCT01757483
- Where
- Canada
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Stroke
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm.
- Trial name
- NCT00129545
- Testing
- WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
- Where
- 62 sites in United States, Czechia and 1 more
- Volunteers
- 800 people
- Sponsor
- Boston Scientific Corporation
Ischemic Ventricular Tachycardia
Therapy Cool Path Ablate VT
To demonstrate that ablation with the Therapy Cool Path Duo cardiac ablation system can eliminate ischemic VT and that its use does not result in an unacceptable risk of serious adverse events.
- Trial name
- Ablate-VT (NCT00925522)
- Testing
- Therapy Cool Path Duo Cardiac Ablation System
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI.
- Trial name
- NCT03635606
- Where
- 3 sites in United States
- Volunteers
- 370 people
- Sponsor
- Sapere Bio
Myocardial Infarction
A Study of NP-011 in Healthy Volunteers
This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.
- Trial name
- NCT05387499
- Testing
- NP-011 (Single Ascending Dose Phase), NP-011 (Multiple Ascending Dose Phase)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Nexel Co., Ltd.
Coronary Atherosclerosis
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries.
- Trial name
- NEVO RES-I (NCT00606333)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
- Where
- 2 sites in Brazil, New Zealand
- Volunteers
- 394 people
- Sponsor
- Cordis US Corp.
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Stenosis
De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions
The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-metal stenting (BMS).
- Trial name
- NCT00934752
- Testing
- Lutonix Paclitaxel-Coated Balloon
- Where
- 3 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- C. R. Bard
Coronary Artery Disease
Perfusion Imaging and CT -Understanding Relative Efficacy
To determine the relative efficacy of Cardiac Computed Tomography Angiography (CCTA) and Single Positron Emission Computed Tomography (SPECT) in patients with an intermediate risk of CAD.
- Trial name
- PICTURE (NCT00486447)
- Testing
- 64 Channel VCT
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- GE Healthcare
Acute Coronary Syndrome
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with…
- Trial name
- NCT01115738
- Testing
- Prasugrel, Clopidogrel
- Where
- 3 sites in India
- Volunteers
- 282 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry
The e-Ultimaster will further validate the safety and efficacy of Ultimaster DES system in unselected patients representing everyday clinical practice.
- Trial name
- e-Ultimaster (NCT02188355)
- Where
- 462 sites in Argentina, Armenia and 48 more
- Volunteers
- 37,000 people
- Sponsor
- Terumo Europe N.V.
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg daily in reducing the concentration of…
- Trial name
- NCT00651404
- Testing
- Ezetimibe
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Coronary Artery Disease
NAVIGATE GRX Study
The objective of the present study is to detail the results of robotic-assisted PCI using technIQ automated movements in real-world clinical practice.
- Trial name
- NCT04883008
- Testing
- CorPath GRX with technIQ automated movements enabled (technIQ ON), CorPath GRX with technIQ automated movements disabled (technIQ OFF).
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
STEMI
Efficacy and Safety on Prouk for STEMI Patients in China
The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded…
- Trial name
- NCT02367976
- Testing
- rhprouk
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd
Coronary Artery Disease, Coronary Stenosis
TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the rapamycin target eluting stent in the treatment of subjects with ischemic heart disease (asymptomatic myocardial ischemia , table or unstable…
- Trial name
- T-P (NCT04951050)
- Testing
- Rapamycin target eluting stent
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Dilated Cardiomyopathy
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
This study is designed to assess the safety and tolerability of Cardiac Repair Cells (CRCs) compared to standard-of-care in patients with dilated cardiomyopathy (DCM).
- Trial name
- NCT00765518
- Testing
- Ixmyelocel-T, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vericel Corporation
Stable Angina
Stable Angina Observational Registry
The purpose of this study is to describe the clinical profile and current status of the diagnosis and management of stable angina in India by non-interventional consulting physicians (CP) through a large multicenter observational…
- Trial name
- STAR (NCT01552109)
- Where
- India
- Volunteers
- 2,079 people
- Sponsor
- Medtronic Vascular